Inceptor Bio is a cancer cell therapy developer in the United States, focusing on the development of its CAR-M and CAR-NK platforms, and its main CAR-T project has entered Phase 1 clinical trials. The company’s CAR-T, CAR-M and CAR-NK platforms Focuses on enhancing cell performance in the tumor microenvironment through innovative mechanisms. Recently, Inceptor Bio received $37 million in Series A financing, led by Kineticos Ventures.
This article is reproduced from: https://www.itjuzi.com/investevent/13234866
This site is for inclusion only, and the copyright belongs to the original author.